Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma

The introduction of tyrosine kinase inhibitors (TKIs) against vascular endothelial growth factor receptors (VEGFRs) has transformed the therapeutic landscape for patients with advanced renal cell carcinoma (RCC). However, dose reductions and interruptions are frequently needed due to limited toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakellakis, Minas, Zakopoulou, Roubini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066464/
https://www.ncbi.nlm.nih.gov/pubmed/37012938
http://dx.doi.org/10.7759/cureus.35675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066464/
https://www.ncbi.nlm.nih.gov/pubmed/37012938
http://dx.doi.org/10.7759/cureus.35675

Ejemplares similares